Withdrawal of inhaled glucocorticoids and exacerbations of COPD by Magnussen, Helgo et al.
n engl j med 371;14 nejm.org october 2, 2014 1285
The new england  
journal of medicine
established in 1812 october 2, 2014 vol. 371 no. 14
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
Helgo Magnussen, M.D., Bernd Disse, M.D., Ph.D., Roberto Rodriguez-Roisin, M.D., Anne Kirsten, M.D.,  
Henrik Watz, M.D., Kay Tetzlaff, M.D., Lesley Towse, B.Sc., Helen Finnigan, M.Sc., Ronald Dahl, M.D.,  
Marc Decramer, M.D., Ph.D., Pascal Chanez, M.D., Ph.D., Emiel F.M. Wouters, M.D., Ph.D.,  
and Peter M.A. Calverley, M.D., for the WISDOM Investigators*
A bs tr ac t
The authors’ affiliations are listed in the 
Appendix. Address reprint requests to 
Dr. Magnussen at the Pulmonary Research 
Institute at Lung Clinic Grosshansdorf, 
Woehrendamm 80, D-22927 Gross hans-
dorf, Germany, or at magnussen@ 
pulmoresearch.de.
*Investigators in the Withdrawal of Inhaled 
Steroids during Optimized Bronchodila-
tor Management (WISDOM) study are 
listed in the Supplementary Appendix, 
available at NEJM.org.
This article was published on September 8, 
2014, and updated on October 2, 2014, at 
NEJM.org. 
N Engl J Med 2014;371:1285-94.
DOI: 10.1056/NEJMoa1407154
Copyright © 2014 Massachusetts Medical Society.
Background
Treatment with inhaled glucocorticoids in combination with long-acting broncho-
dilators is recommended in patients with frequent exacerbations of severe chronic 
obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorti-
coids in addition to two long-acting bronchodilators has not been fully explored.
Methods
In this 12-month, double-blind, parallel-group study, 2485 patients with a history of 
exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 
18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid 
fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients 
were then randomly assigned to continued triple therapy or withdrawal of flutica-
sone in three steps over a 12-week period. The primary end point was the time to 
the first moderate or severe COPD exacerbation. Spirometric findings, health status, 
and dyspnea were also monitored.
Results
As compared with continued glucocorticoid use, glucocorticoid withdrawal met the 
prespecified noninferiority criterion of 1.20 for the upper limit of the 95% confidence 
interval (CI) with respect to the first moderate or severe COPD exacerbation (hazard 
ratio, 1.06; 95% CI, 0.94 to 1.19). At week 18, when glucocorticoid withdrawal was 
complete, the adjusted mean reduction from baseline in the trough forced expira-
tory volume in 1 second was 38 ml greater in the glucocorticoid-withdrawal group 
than in the glucocorticoid-continuation group (P<0.001); a similar between-group 
difference (43 ml) was seen at week 52 (P = 0.001). No change in dyspnea and minor 
changes in health status occurred in the glucocorticoid-withdrawal group.
Conclusions
In patients with severe COPD receiving tiotropium plus salmeterol, the risk of mod-
erate or severe exacerbations was similar among those who discontinued inhaled 
glucocorticoids and those who continued glucocorticoid therapy. However, there 
was a greater decrease in lung function during the final step of glucocorticoid 
withdrawal. (Funded by Boehringer Ingelheim Pharma; WISDOM ClinicalTrials.gov 
number, NCT00975195.)
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Exacerbations of chronic obstruc-tive pulmonary disease (COPD) are symp-tomatically defined, acute events that lead 
to a change in treatment1,2 and are associated 
with an accelerated decline in lung function and 
health status.3 Treatment with inhaled glucocor-
ticoids reduces the exacerbation rate, especially 
when the drugs are used in combination with a 
long-acting β-agonist (LABA).4,5 Consequently, 
combination therapy with an inhaled glucocorti-
coid and a LABA is recommended in patients 
with severe COPD or a history of frequent exacer-
bations.2 Long-acting muscarinic antagonists 
(LAMAs) have also been shown to prevent exac-
erbations.6-8 However, in patients with severe or 
very severe COPD and a history of exacerbations, 
the benefit of inhaled glucocorticoids in a regi-
men that includes these two classes of long-act-
ing bronchodilators has not yet been determined 
in an adequately powered study.
We hypothesized that with a controlled, step-
wise withdrawal of inhaled glucocorticoids, the 
risk of exacerbation would be similar to that with 
continued use of inhaled glucocorticoids in pa-
tients with severe or very severe COPD who were 
receiving a combination of a LAMA (tiotropium) 
and a LABA (salmeterol). To test this hypothesis, 
we conducted the Withdrawal of Inhaled Steroids 
during Optimized Bronchodilator Management 
(WISDOM) trial, which was designed to deter-
mine whether patients with COPD who were re-
ceiving both LAMA and LABA therapy with in-
haled glucocorticoids would have similar outcomes 
regardless of whether the glucocorticoids were 
withdrawn or continued.
Me thods
Study Design
From February 2009 through July 2013, we per-
formed this multinational, randomized, double-
blind, parallel-group, active-control study. All pa-
tients entered a 6-week run-in period during which 
they received 18 μg of tiotropium once daily (de-
livered by a HandiHaler), 50 μg of salmeterol xina-
foate twice daily (two actuations of 25 μg; a dose 
of 21 μg is designated on the U.S. product label), 
and 500 μg of fluticasone propionate (an inhaled 
glucocorticoid) twice daily (two actuations of 250 
μg [U.S. designated dose, 230 μg] delivered by a 
metered-dose inhaler). In this study, we refer to 
the European Union designation of doses for 
consistency.
During the double-blind phase of the trial, 
patients underwent randomization in a 1:1 ratio 
to the two study groups. The first group contin-
ued to receive tiotropium, salmeterol, and flu tic-
asone at the same doses as those used during 
the run-in period for the duration of the 52-week 
study period. The second group continued to re-
ceive tiotropium and salmeterol over the 52-week 
period but with a stepwise reduction in the flutic-
asone dose every 6 weeks, from a total daily dose 
of 1000 μg to 500 μg, then to 200 μg, and finally 
to 0 μg (placebo)9 (Fig. S1 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org). Patients who prematurely dis-
continued therapy were followed for vital status 
from the time of discontinuation until the com-
pletion of the trial at 52 weeks.
Patients
We recruited patients who were at least 40 years 
of age and who were either current smokers (≥10 
pack-years) or former smokers and had received a 
diagnosis of severe or very severe COPD, which 
was defined as a forced expiratory volume in 
1 second (FEV1) that was less than 50% of the 
predicted volume and less than 70% of the forced 
vital capacity after bronchodilation and a history 
of at least one documented exacerbation in the 
12 months before screening. Full inclusion and 
exclusion criteria have been reported previously 9 
and are provided in the trial protocol, which is 
available at NEJM.org. All patients provided writ-
ten informed consent.
The use of xanthines and mucolytic agents, but 
not maintenance oral glucocorticoid treatment, 
was allowed throughout the trial. All patients 
were provided with open-label salbutamol (also 
known as albuterol) for use as needed. At the 
investigator’s discretion, randomized treatment 
could be discontinued and open-label fluticasone 
could be initiated for the remainder of the trial. 
Any exacerbations that were reported after the 
discontinuation of randomized treatment were not 
included in the primary end point. Included in a 
prespecified sensitivity analysis were exacerbations 
that were reported in patients who were receiving 
open-label fluticasone therapy and in those who 
had discontinued treatment.
End Points and Assessments
The primary end point was the time to the first 
moderate or severe COPD exacerbation during 
the 12-month study period. We used a standard-
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ized, structured questionnaire to collect data re-
garding exacerbations, with documentation at 
each study visit. In addition, we provided patients 
with a simple diary, to be completed on a daily 
basis, for noting changes in symptoms and the 
use of medications between visits. A moderate 
exacerbation was defined as an increase in lower 
respiratory tract symptoms related to COPD or 
the new onset of two or more such symptoms, 
with at least one symptom lasting 3 or more days 
and for which the treating physician prescribed 
antibiotics, systemic glucocorticoids, or both. A 
severe exacerbation was defined as an exacerba-
tion requiring hospitalization in an urgent care 
unit. The start date of an exacerbation was de-
fined as the onset date of the first recorded COPD 
symptom.
Secondary end points included the time to the 
first severe COPD exacerbation, the number of 
moderate or severe COPD exacerbations, the 
change from baseline in lung function (including 
the trough FEV1, forced vital capacity, and peak 
expiratory flow rate), health status, and dyspnea. 
To assess health status, we used the total score 
on the St. George’s Respiratory Questionnaire 
(SGRQ), on a scale of 0 to 100, with higher scores 
indicating worse function and a minimum clini-
cally important difference of 4 points.10 To as-
sess dyspnea, we used the modified Medical 
Research Council (mMRC) scale of 0 to 4, with 
higher scores indicating more severe dyspnea; the 
absence of breathlessness was given a score of −1. 
No minimum clinically important difference has 
been identified.11 All secondary end points were 
assessed over the 12-month study period.
We performed all spirometric measurements 
according to the recommendations of the American 
Thoracic Society and the European Respiratory 
Society12 at baseline and at weeks 6, 12, 18, and 
52. We used values after bronchodilation in quali-
fying tests of pulmonary function. Before per-
forming spirometric testing, we obtained scores 
on the SGRQ at baseline and at weeks 27 and 52 
and obtained scores on the mMRC scale at base-
line and at weeks 18 and 52. (Additional details 
regarding the end points are provided in the 
protocol and in Table S1 in the Supplementary 
Appendix.)
Safety
We performed physical examinations at the time 
of screening and at week 52 and measured and 
recorded vital signs at baseline and at weeks 6, 12, 
18, and 52. Chest radiography was requested when 
pneumonia was suspected during the trial. Ad-
verse events and serious adverse events, regard-
less of causality, were recorded throughout the 
study, and results are reported descriptively. If pa-
tients did not spontaneously report adverse events, 
they were asked open-ended questions, such as 
“How have you felt since the last visit?”
Study Oversight
The study protocol was approved by the ethics 
review board at each institution. The first draft 
of the manuscript and subsequent revisions were 
written by the academic authors, and all the au-
thors worked collaboratively to prepare the final 
content; all the authors made the decision to sub-
mit the manuscript for publication. Editorial as-
sistance was provided by a medical writer employed 
by a company that was paid by the study sponsor, 
Boehringer Ingelheim Pharma. Statistical analyses 
were performed by the sponsor. All study drugs 
were supplied by the sponsor. All the authors 
vouch for the accuracy and completeness of the 
data and the fidelity of the study to the protocol.
Statistical Analysis
We estimated that 2456 patients would need to 
undergo randomization at the 200 study centers 
to ensure a minimum of 2234 patients who could 
be evaluated in order to provide the study with a 
power of 90% to determine the noninferiority of 
the hazard ratio for exacerbation among patients 
in the glucocorticoid-withdrawal group, as com-
pared with the glucocorticoid-continuation group, 
with a one-sided alpha level of 0.025 and an ex-
pected dropout rate of 15% per year. The as-
sumed median time to the first primary event was 
9 months. The prespecified noninferiority margin 
of 1.20 was defined as the upper limit of the 95% 
confidence interval for the hazard ratio for the 
first moderate or severe exacerbation in the glu-
cocorticoid-withdrawal group, as compared with 
the glucocorticoid-continuation group. Both ef-
ficacy and safety were evaluated in the modified 
intention-to-treat population, which was defined 
as all patients who received at least one dose of a 
study drug.
We used a Cox proportional-hazards regression 
model with adjustment for the baseline FEV1 in 
the primary analysis, in the prespecified sensi-
tivity analysis, and in the analysis of the time to 
the first severe COPD exacerbation. In the sensi-
tivity analysis, we included exacerbations in pa-
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tients who were switched to open-label f lutica-
sone. In a post hoc sensitivity analysis of the 
primary end point, we removed the covariate from 
the model in order to include treated patients 
with missing data regarding the baseline FEV1. 
In addition, we used the Kaplan–Meier method 
to estimate the probability of a moderate or se-
vere COPD exacerbation. This procedure was re-
peated for determining the probability of a severe 
COPD exacerbation. Additional details regard-
ing the statistical analysis are provided in the 
protocol and in Section 4 in the Supplementary 
Appendix.
R esult s
Patients
A total of 2485 patients underwent randomization 
at 200 centers in 23 countries. A total of 82.5% of 
the patients were men; the mean age was 63.8 
years, and the mean FEV1 after bronchodilation 
was 0.93 liters, which was 32.8% of the predicted 
value. Of the 2485 patients, 2027 completed the 
52-week study, including those who received open-
label fluticasone.
Characteristics of the patients at baseline and 
dropout rates were similar in the two study groups 
(Fig. 1 and Table 1, and Table S2 in the Sup ple-
mentary Appendix). According to the Global Initi-
ative for Chronic Obstructive Lung Disease (GOLD) 
criteria, 61.2% of the patients had an FEV1 that 
was 30 to 49% of the predicted value (GOLD 3), 
and 38.1% of the patients had an FEV1 that was 
less than 30% of the predicted value (GOLD 4). 
The percentages of patients receiving inhaled glu-
cocorticoids, LABAs, or LAMAs at baseline were 
69.9%, 64.6%, and 46.9%, respectively, with 39.0% 
receiving the three treatments in combination. 
2488 Underwent randomization
3426 Patients were enrolled
938 Were excluded
72 (7.7%) Had adverse event
679 (72.4%) Did not meet inclusion criteria 
       or met exclusion criteria
13 (1.4%) Were lost to follow-up
117 (12.5%) Withdrew consent
57 (6.1%) Had other reason
1244 Were assigned to glucocorticoid
continuation
1244 Were assigned to glucocorticoid
withdrawal
227 Discontinued study
108 Had adverse event
6 Had lack of efficacy
27 Did not adhere to study 
     regimen
9 Were lost to follow-up
48 Declined study
medication
29 Had other reason
231 Discontinued study
101 Had adverse event
6 Had lack of efficacy
23 Did not adhere to study 
     regimen
7 Were lost to follow-up
61 Declined study
medication
33 Had other reason
1243 Were treated 1242 Were treated
1016 (81.7%) Completed study 1011 (81.4%) Completed study
Figure 1. Enrollment and Outcomes.
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Overall, 28.2% of patients had cardiac disorders at 
baseline, and 45.8% had vascular disorders (Table 
S3 in the Supplementary Appendix).
Primary End Point
The hazard ratio for a first moderate or severe 
COPD exacerbation was 1.06 (95% confidence in-
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Glucocorticoid 
Continuation
(N = 1243)
Glucocorticoid 
Withdrawal 
(N = 1242)
All Patients
(N = 2485)
Male sex — no. (%) 1013 (81.5) 1036 (83.4) 2049 (82.5)
Age — yr 63.6±8.6 64.0±8.4 63.8±8.5
Former smoker — no. (%)† 811 (65.2) 843 (67.9) 1654 (66.6)
Duration of COPD — yr 7.75±5.99 8.00±6.47 7.87±6.23
Percentage of predicted FEV1 after  
bronchodilation — no. (%)
30–49%: GOLD 3 760 (61.1) 761 (61.3) 1521 (61.2)
<30%: GOLD 4 473 (38.1) 474 (38.2) 947 (38.1)
Other category‡ 10 (0.8) 7 (0.6) 17 (0.7)
Baseline lung function§
Patients with available data — no. 1223 1218 2441
FEV1
Value — liters 0.97±0.36 0.98±0.36 0.98±0.36
Percentage of predicted value 34.2±11.2 34.3±10.8 34.2±11.0
Score on mMRC scale¶
Patients with available data — no. 1238 1237 2475
Mean score 1.8±0.9 1.9±0.9 1.8±0.9
SGRQ score‖
Patients with available data — no. 1136 1126 2262
Mean score 46.35±17.89 45.91±18.19 46.13±18.04
Medication use — no. (%)
LAMA 588 (47.3) 578 (46.5) 1166 (46.9)
LABA 807 (64.9) 798 (64.3) 1605 (64.6)
Inhaled glucocorticoid 876 (70.5) 862 (69.4) 1738 (69.9)
Triple therapy with LAMA, LABA, and inhaled 
glucocorticoid, with or without other 
pulmonary medication — no. (%)**
479 (38.5) 491 (39.5) 970 (39.0)
* Plus–minus values are means ±SD. There were no significant differences between the two groups at baseline on the 
basis of t-tests for continuous variables and chi-square tests or Fisher’s exact test, as appropriate, for categorical variables. 
COPD denotes chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 second, GOLD Global Ini tiative 
for Chronic Obstructive Lung Disease, LABA long-acting β-agonist, and LAMA long-acting muscarinic antagonist.
† All patients in the study were either current smokers (≥10 pack-years) or former smokers.
‡ Of the 17 patients in this category, 3 had mild COPD (FEV1, ≥80% of predicted value, or GOLD 1), 9 had moderate 
COPD (FEV1, 50 to 79% of predicted value, or GOLD 2), and 5 had missing values.
§ Patients for whom baseline lung-function data were available were evaluated after receiving triple therapy during the 
run-in period. Usable data regarding lung function were missing for 44 patients at baseline. 
¶ Scores on the modified Medical Research Council (mMRC) scale range from 0 to 4, with higher scores indicating more 
severe dyspnea; the absence of breathlessness was given a score of −1. No minimum clinically important difference 
has been identified.
‖ Scores on St. George’s Respiratory Questionnaire (SGRQ) range from 0 to 100, with higher scores indicating worse 
function and a minimum clinically important difference of 4 points.
** Other respiratory medications included oral β-agonists, oral glucocorticoids, leukotriene-receptor antagonists, muco-
lytic agents, oxygen, and xanthines.
The New England Journal of Medicine 
Downloaded from nejm.org on May 2, 2018. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;14 nejm.org october 2, 20141290
terval [CI], 0.94 to 1.19) with glucocorticoid with-
drawal as compared with glucocorticoid continu-
ation, which indicated noninferiority, since the 
upper limit of the confidence interval was below 
the predefined noninferiority margin of 1.20 
(Fig. 2A and 2B). The results were similar in a 
sensitivity analysis that included exacerbations 
occurring after patients had discontinued random-
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Figure 2. COPD Exacerbations and Lung Function.
Panel A shows Kaplan–Meier curves for the estimated probability of moderate or severe exacerbations of chronic obstructive pulmonary 
disease (COPD) during the study, with no significant difference between the group assigned to withdrawal of inhaled glucocorticoids 
(IGC) and the group assigned to continued IGC treatment. Panel B shows a forest plot of hazard ratios for the first COPD exacerbation 
(the primary end point), the primary end point including exacerbations during open-label therapy (sensitivity analysis), and the primary 
end point excluding the covariate of the baseline forced expiratory volume in 1 second (FEV1) (sensitivity analysis). All three categories 
fall within the prespecified noninferiority margin of 1.20 (the upper limit of the 95% confidence interval for the hazard ratio in the gluco-
corticoid-withdrawal group as compared with the glucocorticoid-continuation group). Horizontal dashed lines indicate 95% confidence 
intervals. Panel C shows Kaplan–Meier curves for the estimated probability of severe COPD exacerbations, with no significant between-
group difference. Panel D shows the adjusted mean change from baseline in the FEV1, as measured during clinic visits. In the glucocorticoid-
withdrawal group, there was a significant decline in lung function at weeks 18 and 52, as compared with the change from baseline in the 
glucocorticoid-continuation group. I bars indicate standard errors. In Panels A and C, the study period ends at 54 weeks because some 
visits could not be scheduled at 52 weeks.
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ized treatment and in a post hoc analysis that 
excluded the FEV1 from the model (Fig. 2B, and 
Fig. S2 in the Supplementary Appendix). The time 
by which 25% of patients had a first moderate or 
severe exacerbation (first quartile) was 110 days 
in the glucocorticoid-withdrawal group and 107 
days in the glucocorticoid-continuation group.
Secondary End Points
The adjusted event rate for moderate or severe 
exacerbations was 0.95 per patient-year (95% CI, 
0.87 to 1.04) in the glucocorticoid-withdrawal 
group and 0.91 per patient-year (95% CI, 0.83 to 
0.99) in the glucocorticoid-continuation group. 
Analysis of the time to the first severe COPD ex-
acerbation showed a hazard ratio of 1.20 (95% CI, 
0.98 to 1.48) for glucocorticoid withdrawal as com-
pared with glucocorticoid continuation (Fig. 2C). 
The majority of patients with one or more exac-
erbations had one or two moderate or severe ex-
acerbations during the study (Fig. S3 and S4 in the 
Supplementary Appendix). There were no signifi-
cant between-group differences in hazard ratios 
in any of the subgroup analyses (Fig. 3).
FEV1
At week 18, when glucocorticoid withdrawal was 
complete, the adjusted mean reduction from base-
line in the trough FEV1 was 38 ml greater in the 
glucocorticoid-withdrawal group than in the glu-
cocorticoid-continuation group (P<0.001). A sim-
ilar between-group difference (43 ml) was seen at 
week 52 (Fig. 2D). No significant between-group 
differences were observed at weeks 6 and 12.
Health Status
The change from baseline in the mMRC score 
did not differ significantly between the glucocor-
ticoid-withdrawal group and the glucocorticoid-
continuation group at week 18 (−0.001 and −0.030 
points, respectively; P = 0.36) or at week 52 (0.035 
and −0.028 points, respectively; P = 0.06). The 
changes from baseline in the total SGRQ scores 
were an increase of 0.55 points in the glucocorti-
coid-withdrawal group and a reduction of 0.42 
points in the glucocorticoid-continuation group 
at week 27 (P = 0.08) and an increase of 1.15 and 
a decrease of 0.07, respectively, at week 52 
(P = 0.047).
Safety
The overall proportion of patients who had one 
or more adverse events while receiving the study 
treatment was 71.2%, and the proportions were 
similar in the two groups (Table 2, and Table S4 
in the Supplementary Appendix). Serious adverse 
events were reported in 24.2% of the patients in 
the glucocorticoid-withdrawal group and 23.5% 
of the patients in the glucocorticoid-continuation 
group. Rates of fatal adverse events were 3.2% in 
the glucocorticoid-withdrawal group and 2.7% in 
the glucocorticoid-continuation group.
The incidence of pneumonia was 5.5% in the 
glucocorticoid-withdrawal group and 5.8% in 
the glucocorticoid-continuation group. The inci-
dence of cardiac adverse events of interest was 
similarly balanced between the groups, with major 
adverse cardiac events reported in 2.2% of the 
patients in the glucocorticoid-withdrawal group 
and 2.0% of patients in the glucocorticoid-con-
tinuation group. Major adverse cardiac events that 
were fatal were reported in 1.5% and 1.1% of the 
patients, respectively, and stroke was reported 
in 0.5% and 0.7% of the patients, respectively 
(Table 2).
Discussion
In our study, in which patients with severe or very 
severe COPD received triple therapy with a LAMA, 
a LABA, and an inhaled glucocorticoid during a 
run-in period, followed by withdrawal of the in-
haled glucocorticoid over a 3-month period or 
continued triple therapy, the upper limit of the 
95% confidence interval for an increase in the 
risk of a moderate or severe acute exacerbation 
was below the prespecified noninferiority margin 
of 1.20 in the glucocorticoid-withdrawal group. 
Differences in FEV1 and health status emerged in 
the 18-week analysis after inhaled glucocorticoid 
treatment was completely withdrawn. We did not 
identify any subgroup of patients that had an in-
creased likelihood of an exacerbation after glu-
cocorticoid withdrawal. Since a history of exacer-
bation and substantial impairment in lung function 
were entry criteria, our study population was rep-
resentative of patients for whom inhaled gluco-
corticoids are recommended on the basis of 
GOLD guidance.1
Most clinical trials involving patients with 
COPD have established the benefit of treatment 
by comparing a new therapy with placebo or a 
relevant active control. Few trials have considered 
the question of whether such therapy should be 
continued after clinical stability has been achieved, 
an approach that is commonly adopted for pa-
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tients with asthma.13 Initial studies showed that 
abrupt withdrawal of inhaled glucocorticoids in 
patients with a range of COPD severities led to 
more exacerbations and some worsening of lung 
function, at least when patients used short-acting 
bronchodilators as maintenance treatment.14-17 
In our study, we used dual bronchodilation with 
salmeterol and tiotropium, which has proved to 
be more effective than salmeterol alone in the 
prevention of exacerbations.6 Moreover, we with-
drew glucocorticoid treatment gradually from a 
common baseline of maximized therapy.
In our study, we saw no significant between-
group difference in the rate of dropout, which 
typically occurs more frequently in the placebo 
groups in clinical trials.18,19 There was a tran-
1.0 2.0
IGC Continuation BetterIGC Withdrawal Better
All patients
Age
<55 yr
≥55 to <65 yr
≥65 to <75 yr
≥75 yr
Sex
Male
Female
Smoking status
Former smoker
Current smoker
Body-mass index
<20
≥20 to <25
≥25 to <30
≥30
IGC at screening
Yes
No
Xanthines at screening
Yes
No
Chronic bronchitis
Yes
No
GOLD stage at screening
3
4
GOLD assessment category at baseline
C
D
Prior antibiotics or systemic glucocorticoids
<2
≥2
Beta-blockers at screening
Yes
No
No. of Patients Hazard Ratio (95% CI)Subgroup
2441
345
945
883
268
2010
431
1630
811
368
912
771
390
1724
717
567
1874
1548
891
1491
934
819
1612
1537
903
188
2253
0.5
1.04
0.95
1.19
1.06
1.08
1.02
1.10
0.99
0.94
1.17
1.05
0.96
1.08
1.00
1.15
1.03
1.11
0.95
1.12
1.00
1.15
1.01
1.03
1.11
0.89
1.07
1.06
Figure 3. Subgroup Analyses of the First Moderate or Severe COPD Exacerbation in All Study Patients.
All categories were evaluated in post hoc analyses except for age, sex, smoking status, and baseline body-mass in-
dex. Data with respect to chronic bronchitis were obtained from electronic case-report forms. The size of the dia-
monds is proportional to the number of patients in the subgroup. The horizontal lines indicate 95% confidence 
intervals. Usable data regarding lung function were missing for 44 patients at baseline. GOLD denotes Global 
Initiative for Chronic Obstructive Lung Disease.
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sient increase in the number of severe exacerba-
tions soon after the complete withdrawal of 
glucocorticoids, but this increase was not sig-
nificant and was not sustained during the study 
period. We considered a number of subgroups in 
which a greater degree of dependence on gluco-
corticoids might be expected, but we did not find 
notable differences in outcomes between inhaled 
glucocorticoid withdrawal and continued triple 
therapy in any of these subgroups.
After complete withdrawal of glucocorticoids, 
we observed a small but significant and persis-
tent between-group difference in the FEV1, with 
a larger reduction from the baseline value in the 
glucocorticoid-withdrawal group. This change 
was similar to that observed in previous trials of 
glucocorticoid withdrawal14-17 and in a study of 
roflumilast, an oral nonglucocorticoid antiin-
flammatory drug, in a patient population that was 
similar to the one in our study.20 The change in 
the FEV1 may represent the spirometric signal 
associated with antiinflammatory therapy but 
does not seem to be associated with exacerba-
tions, as reported in recent studies of combina-
tion therapy with once-daily inhaled glucocorti-
coids plus LABAs.21 In our study, the between-group 
difference in FEV1 became apparent only after the 
final step of inhaled glucocorticoid withdrawal 
(from 200 μg to 0 μg of fluticasone per day).
We saw no significant effect of glucocorticoid 
withdrawal on the mMRC score, but there was a 
difference in the total SGRQ score that was 
noted during the study period and that favored 
continued glucocorticoid therapy. However, the 
importance of this finding is unclear, since the 
between-group difference was smaller than the 
frequently used minimum clinically important 
difference22 and was not related to differences in 
the number of exacerbations. We saw no sig-
nificant between-group difference in the safety 
profile, including the number of cases of pneu-
monia. In contrast, other studies have shown an 
increase in cases of pneumonia among patients 
with COPD who received fluticasone.5,8,21 On the 
basis of our study data, we cannot determine 
whether our findings with respect to pneumonia 
reflect differences in our patient population or a 
sustained effect on pneumonia risk in our glu-
cocorticoid-withdrawal group, since patients in 
that group received inhaled glucocorticoids for 
4 months (including the run-in period); this 
question merits future study.
Our study has both strengths and limitations. 
We enrolled substantially more patients than were 
enrolled in all previous trials of glucocorticoid 
withdrawal combined, which allowed for further 
examination of the response in various subgroups. 
We had 9 months of observation of patients who 
were not receiving glucocorticoids, with no sug-
gestion that exacerbations were occurring more 
frequently. It is unlikely that a longer follow-up 
period would have changed this conclusion. Our 
study population consisted mainly of white men; 
we believe that the proportionally smaller enroll-
ment of women was the result of a combination of 
disease prevalence in the study countries and the 
severity of disease within our population. However, 
we observed no significant difference in outcome 
on the basis of sex (Fig. 3).
Table 2. Adverse Events.*
Variable
Glucocorticoid 
Continuation
(N = 1243)
Glucocorticoid 
Withdrawal
(N = 1242)
no. of patients (%)
Adverse events
Any 880 (70.8) 890 (71.7)
Leading to discontinuation  
of study drug
115 (9.3) 127 (10.2)
Serious adverse events
Any 292 (23.5) 300 (24.2)
Death
During study period 34 (2.7) 40 (3.2)
Including vital-status follow-up 38 (3.1) 43 (3.5)
Requiring hospitalization 273 (22.0) 271 (21.8)
Adverse events of special interest†
Pneumonia 72 (5.8) 68 (5.5)
Major adverse cardiac event
Any 25 (2.0) 27 (2.2)
Fatal 14 (1.1) 19 (1.5)
Stroke 9 (0.7) 6 (0.5)
* A more detailed list of adverse events is provided in Table S4 in the Supple-
mentary Appendix.
† The preferred terms in the Medical Dictionary for Regulatory Activities 
(MedDRA) that were included in the category of pneumonia were broncho-
pneumonia, lobar pneumonia, pneumonia, pneumonia klebsiella, pneumonia 
pneumococcal, and pneumonia streptococcal; the system organ classes that 
were included in the category of major adverse cardiac events were cardiac dis-
orders (fatal) and vascular disorders (fatal); the preferred terms were sudden 
death, cardiac death, and sudden cardiac death; the Standardized MedDRA 
query (SMQ) was ischemic heart disease, and the sub-SMQs were myocardial 
infarction (broad) and myocardial infarction (fatal); and those that were in-
cluded in the category of stroke were cerebellar infarction, cerebral infarction, 
cerebrovascular accident, embolic cerebral infarction, ischemic cerebral infarc-
tion, ischemic stroke, and transient ischemic attack.
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In conclusion, we found that in patients with 
severe but stable COPD who were receiving com-
bination therapy with tiotropium, salmeterol, 
and glucocorticoids, the stepwise withdrawal of 
glucocorticoids was noninferior to the continua-
tion of such therapy, with respect to the risk of 
moderate or severe exacerbations. The effect of 
withdrawal on symptoms and lung function also 
needs to be considered when making decisions 
regarding maintenance therapy in patients with 
severe but stable COPD.
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